ORIC Pharmaceuticals (FRA:4TZ) EBITDA Margin %: 0.00% (As of Mar. 2026)


FRA:4TZ ORIC Pharmaceuticals Inc FRA:4TZ
32 GF Score
Price €9.13
! 3 Warning Signs
View Full Analysis

What is ORIC Pharmaceuticals EBITDA Margin %?

ORIC Pharmaceuticals FRA:4TZ -2.77% 32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 937 Biotechnology companies, ORIC Pharmaceuticals ranks worse than 106723.48% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ORIC Pharmaceuticals's EBITDA for the three months ended in Mar. 2026 was €-34.04 Mil. ORIC Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, ORIC Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

ORIC Pharmaceuticals  (FRA:4TZ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

ORIC Pharmaceuticals EBITDA Margin % Related Terms

ORIC Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for ORIC Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ORIC Pharmaceuticals EBITDA Margin % Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ORIC Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:4TZ vs DRTS, OLMA, KURA: EBITDA Margin % Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ORIC Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's EBITDA Margin % falls into.


FRA:4TZ
32GF Score
ORIC Pharmaceuticals Inc FRA:4TZ
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ORIC Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ORIC Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-121.084/0
= %

ORIC Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-34.037/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
ORIC Pharmaceuticals (FRA:4TZ) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ORIC Pharmaceuticals and its competitors. According to the industry distribution chart, ORIC Pharmaceuticals ranks #999999 out of 937 companies in the Biotechnology industry.
Is ORIC Pharmaceuticals' EBITDA Margin % too high?
ORIC Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, ORIC Pharmaceuticals ranks #999999 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ORIC Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' EBITDA Margin % compare to DRTS and OLMA?
According to the Biotechnology industry distribution chart, ORIC Pharmaceuticals ranks #999999 out of 937 companies for EBITDA Margin %. This places ORIC Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ORIC Pharmaceuticals and its competitors. ORIC Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. ORIC Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ORIC Pharmaceuticals Business Description

Other Exchanges ORIC:USA
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
32GF Score

Get the complete analysis for FRA:4TZ

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.13
Price